MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
he company will focus on production of any pharmaceutical and biotechnological products
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
This is used to treat central diabetes insipidus and bedwetting
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
The inspection conducted by EDQM at its Visakhapatnam facility
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Subscribe To Our Newsletter & Stay Updated
